Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye provides a research update following the Q2 report published by Alzinova earlier today.</li><li>The financials in the report contained no major surprises, being overall in line with our expectations.</li><li>Importantly, Alzinova has now signed a Letter of Intent (LoI) with Fujirebio regarding its emerging blood-based diagnostic program as the company continues preparations ahead of an upcoming phase II study with ALZ-101.</li></ul>

Redeye provides a research update following the Q2 report published by Alzinova earlier today.The financials in the report contained no major surprises, being overall in line with our expectations.Importantly, Alzinova has now signed a Letter of Intent (LoI) with Fujirebio regarding its emerging blood-based diagnostic program as the company continues preparations ahead of an upcoming phase II study with ALZ-101.

Alzinova (Q2 Review): Capitalizing on diagnostics opportunities